Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review

December 2020 | 50 pages | ID: H1D6E6884C5EN
GlobalData

Abstracts

Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. The company develops drugs based on DOS47, its proprietary broad anti-cancer therapeutic platform. DOS47 has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Ontario, Canada.

Helix BioPharma Corp Key Recent Developments

Jul 30,2020: Helix Biopharma announces fiscal third quarter 2020 results
Jul 13,2020: Helix BioPharma provides update on the timing of filing of third quarter results
Apr 02,2020: Helix BioPharma provides corporate update
Mar 16,2020: Helix BioPharma announces fiscal second quarter 2020 results
Jan 09,2020: Mayo Clinic to sequence 100,000 participants to build genomic database for improved care and research in collaboration with Helix

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Helix BioPharma Corp - Key Facts
Helix BioPharma Corp - Key Employees
Helix BioPharma Corp - Key Employee Biographies
Helix BioPharma Corp - Major Products and Services
Helix BioPharma Corp - History
Helix BioPharma Corp - Company Statement
Helix BioPharma Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Helix BioPharma Corp - Business Description
R&D Overview
Helix BioPharma Corp - Corporate Strategy
Helix BioPharma Corp - SWOT Analysis
SWOT Analysis - Overview
Helix BioPharma Corp - Strengths
Helix BioPharma Corp - Weaknesses
Helix BioPharma Corp - Opportunities
Helix BioPharma Corp - Threats
Helix BioPharma Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Helix BioPharma Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 30, 2020: Helix Biopharma announces fiscal third quarter 2020 results
Jul 13, 2020: Helix BioPharma provides update on the timing of filing of third quarter results
Apr 02, 2020: Helix BioPharma provides corporate update
Mar 16, 2020: Helix BioPharma announces fiscal second quarter 2020 results
Jan 09, 2020: Mayo Clinic to sequence 100,000 participants to build genomic database for improved care and research in collaboration with Helix
Dec 13, 2019: Helix BioPharma announces fiscal first quarter 2020 results
Oct 24, 2019: Helix BioPharma announces fiscal 2019 year-end results
Oct 10, 2019: Helix BioPharma announces Board changes
Jun 11, 2019: Helix BioPharma announces fiscal third quarter 2019 results
May 30, 2019: Helix BioPharma initiates OTCQB application and hires U.S. investor relations firm

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Helix BioPharma Corp, Key Facts
Helix BioPharma Corp, Key Employees
Helix BioPharma Corp, Key Employee Biographies
Helix BioPharma Corp, Major Products and Services
Helix BioPharma Corp, History
Helix BioPharma Corp, Subsidiaries
Helix BioPharma Corp, Key Competitors
Helix BioPharma Corp, Ratios based on current share price
Helix BioPharma Corp, Annual Ratios
Helix BioPharma Corp, Annual Ratios (Cont...1)
Helix BioPharma Corp, Interim Ratios
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Helix BioPharma Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Helix BioPharma Corp, Performance Chart (2016 - 2020)
Helix BioPharma Corp, Ratio Charts
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020